文献速递造血干细胞移植与细胞治疗

急性移植物抗宿主病中的细胞因子与共刺激信号

Cytokines and costimulation in acute graft-versus-host disease.
PubMed 文献 · Blood · 2020-01-01

本文综述急性移植物抗宿主病(aGVHD)中细胞因子网络与共刺激信号在T细胞表面的整合机制。预处理释放的内源性警报素与病原体来源分子激活抗原提呈细胞,后者释放细胞因子并上调共刺激/共抑制信号,驱动供者T细胞效应功能与aGVHD。上述通路为预防aGVHD提供可干预靶点。

要点

  • 预处理释放HMGB-1、ATP、IL-1α、IL-33等警报素,激活抗原提呈细胞。
  • 细胞因子IL-12、IL-23、IL-6、IL-27、IL-10、TGF-β调控致病性与调节性T细胞扩增分化。
  • CD80/CD86-CD28、CD40-CD40L、OX40L-OX40、CD155/CD112-DNAM-1等共刺激信号决定效应T细胞功能。

核心结论

  • 细胞因子与共刺激网络在T细胞表面的整合决定效应功能并最终导致靶组织aGVHD。
  • 上述通路是预防异基因造血干细胞移植后有害免疫启动的稳健且临床可干预靶点。

研究设计与样本

  • 综述:聚焦T细胞表面细胞因子与共刺激网络的组合如何导致效应功能及后续aGVHD。

主要发现

  • 预处理化放疗诱导受者组织释放内源性警报素(如HMGB-1、ATP、IL-1α、IL-33)。
  • 外源性病原体来源分子(如脂多糖、核酸)从胃肠道腔易位。
  • 危险信号激活抗原提呈细胞,使其有效提呈同种抗原并释放IL-12、IL-23、IL-6、IL-27、IL-10、TGF-β等细胞因子。
  • 抗原提呈细胞-T细胞界面的共刺激信号(如CD80/CD86-CD28、CD40-CD40L、OX40L-OX40、CD155/CD112-DNAM-1)与共抑制信号(如CD80/CD86-CTLA4、PDL1/2-PD1、CD155/CD112-TIGIT)对效应T细胞功能获得至关重要。
  • 效应T细胞分泌致病性细胞因子(如IL-17、干扰素-γ、组织坏死因子、粒细胞-巨噬细胞集落刺激因子)并启动穿孔素/颗粒酶等溶细胞脱颗粒通路效应分子。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation (alloSCT) is an important curative therapy for high-risk hematological malignancies, but the development of severe and/or steroid-refractory acute graft-versus-host disease (aGVHD) remains a significant limitation to optimal outcomes. New approaches to prevent and treat aGVHD remain an unmet need that can be best addressed by understanding the complex disease pathophysiology. It is now clear that chemoradiotherapy used prior to alloSCT induces the release of endogenous alarmins (eg, HMGB-1, ATP, IL-1α, IL-33) from recipient tissue. Exogenous pathogen-derived molecules (eg, lipopolysaccharide, nucleic acids) also translocate from the gastrointestinal tract lumen. Together, these danger signals activate antigen-presenting cells (APCs) to efficiently present alloantigen to donor T cells while releasing cytokines (eg, interleukin-12 [IL-12], IL-23, IL-6, IL-27, IL-10, transforming growth factor-β) that expand and differentiate both pathogenic and regulatory donor T cells. Concurrent costimulatory signals at the APC-T-cell interface (eg, CD80/CD86-CD28, CD40-CD40L, OX40L-OX40, CD155/CD112-DNAM-1) and subsequent coinhibitory signals (eg, CD80/CD86-CTLA4, PDL1/2-PD1, CD155/CD112-TIGIT) are critical to the acquisition of effector T-cell function and ensuing secretion of pathogenic cytokines (eg, IL-17, interferon-γ, tissue necrosis factor, granulocyte-macrophage colony-stimulating factor) and cytolytic degranulation pathway effectors (eg, perforin/granzyme). This review focuses on the combination of cytokine and costimulatory networks at the T-cell surface that culminates in effector function and subsequent aGVHD in target tissue. Together, these pathways now represent robust and clinically tractable targets for preventing the initiation of deleterious immunity after alloSCT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hill GR, Koyama M. Cytokines and costimulation in acute graft-versus-host disease. Blood. 2020. PMID: 32526028. doi:10.1182/blood.2019000952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。